In vivo cleaved CDCP1 promotes early tumor dissemination via complexing with activated β1 integrin and induction of FAK/PI3K/Akt motility signaling
about
β1-Integrin and integrin linked kinase regulate astrocytic differentiation of neural stem cells.Galectin-3 induces clustering of CD147 and integrin-β1 transmembrane glycoprotein receptors on the RPE cell surface.Identification of anti-tumour biologics using primary tumour models, 3-D phenotypic screening and image-based multi-parametric profilingAndrogen receptor non-nuclear regulation of prostate cancer cell invasion mediated by Src and matriptase.Insulin-like growth factor binding protein-3 inhibits cell adhesion via suppression of integrin β4 expression.3'3-Diindolylmethane inhibits migration, invasion and metastasis of hepatocellular carcinoma by suppressing FAK signaling.CUB-domain-containing protein 1 overexpression in solid cancers promotes cancer cell growth by activating Src family kinasesDysregulated expression of cell surface glycoprotein CDCP1 in prostate cancerCell line and patient-derived xenograft models reveal elevated CDCP1 as a target in high-grade serous ovarian cancer.Bufalin enhances antitumor effect of paclitaxel on cervical tumorigenesis via inhibiting the integrin α2/β5/FAK signaling pathwayCUB domain-containing protein 1 and the epidermal growth factor receptor cooperate to induce cell detachment.CDCP1 cleavage is necessary for homodimerization-induced migration of triple-negative breast cancer.Targeting CDCP1 dimerization in triple-negative breast cancerNew crossroads for potential therapeutic intervention in cancer - intersections between CDCP1, EGFR family members and downstream signaling pathways.Relationship between gene mutation and lung cancer metastasis.Tumor cell intravasation.Multifunctional roles of PKCδ: Opportunities for targeted therapy in human diseaseElevated CDCP1 predicts poor patient outcome and mediates ovarian clear cell carcinoma by promoting tumor spheroid formation, cell migration and chemoresistance.EGF inhibits constitutive internalization and palmitoylation-dependent degradation of membrane-spanning procancer CDCP1 promoting its availability on the cell surface.Suppression of autophagy by CUB domain-containing protein 1 signaling is essential for anchorage-independent survival of lung cancer cells.CD318 is a ligand for CD6.AGO2 involves the malignant phenotypes and FAK/PI3K/AKT signaling pathway in hypopharyngeal-derived FaDu cells.Anacardic acid induces cell apoptosis of prostatic cancer through autophagy by ER stress/DAPK3/Akt signaling pathway.CDCP1 drives triple-negative breast cancer metastasis through reduction of lipid-droplet abundance and stimulation of fatty acid oxidation.Collagen I promotes hepatocellular carcinoma cell proliferation by regulating integrin β1/FAK signaling pathway in nonalcoholic fatty liver.Common mechanism of pathogenesis in various types of metastatic osteosarcoma.Targeting RAS-driven human cancer cells with antibodies to upregulated and essential cell-surface proteins.Actinidia callosa var. callosa suppresses metastatic potential of human hepatoma cell SK-Hep1 by inhibiting matrix metalloproteinase-2 through PI3K/Akt and MAPK signaling pathways.β1 integrin-mediated multicellular resistance in hepatocellular carcinoma through activation of the FAK/Akt pathway.Gene/protein expression of CAPN1/2-CAST system members is associated with ERK1/2 kinases activity as well as progression and clinical outcome in human laryngeal cancer.The PDGFRβ/ERK1/2 pathway regulates CDCP1 expression in triple-negative breast cancer.Mifepristone inhibits proliferation, migration and invasion of HUUA cells and promotes its apoptosis by regulation of FAK and PI3K/AKT signaling pathway
P2860
Q34011023-98149D6A-A111-43C6-8E82-0CCE10A8BC23Q34905376-AAFECE11-3261-4EEC-872E-23C46276AD4BQ35728113-52165A47-C810-4C96-8D26-6CD4129C6EEAQ35740095-B9C1D19A-BEB6-49E1-BF28-2E21FADBC748Q36020955-708C70D0-89AC-4127-96B3-A6E19AB8B32BQ36414292-26228BB2-92C8-4E6D-AA3B-178B8693F25FQ36601460-FC727101-A517-4093-AAE8-C3F60F46485AQ36685495-F957ABA1-C4E1-442B-A044-DFFB7A14A462Q36750564-EA3D3A50-C11E-4519-B8C5-459B55304A27Q36962445-9134CE42-AF00-4E4E-9896-A363BE431791Q37154185-AE190E7E-072B-45DF-A4DB-9273031BB55AQ37176588-8D482EE1-333D-4028-A086-48D1AAF57B79Q37262893-FAA509D1-D9C8-4B0F-A295-C6F7A6CAED16Q38388622-76E5C611-7827-45F9-BE1D-302F61F7D6D7Q38456340-4401175B-EA48-4BBA-9E15-93F4CFE4C0B4Q38807918-A06097FA-FE29-4199-A317-42B5967A198AQ38834586-81EB2020-4D65-43D0-9B50-7B6E635773B0Q38884686-8BAEA13F-B093-4011-810E-C8DFC71CDC18Q39010253-898CD04D-157F-4047-80A7-4778E18531D8Q39178569-3AFF87B7-4714-4837-BCA7-54198354256AQ41476987-5B95816B-AA79-4FA8-9BB3-F09119484CC7Q41550860-BE1AE86E-4748-4353-84D0-22BA314005EFQ42838192-1DFB3A2C-D740-476A-AF3F-A921950C17BDQ46085514-1F54FF14-80D9-4B6C-989F-E19A13DB1485Q47113983-C312C8DF-8D3F-40EE-86B9-D01855A22778Q47130991-9F27183E-0767-45AF-9B5E-1535104A2ADAQ48187016-DEDF8C16-67AC-4E7D-9161-C65B2435A3C5Q49291960-0AD87761-9B49-4F97-849B-8BE72B75FD81Q50052675-D3FEA898-D03C-4050-A687-81E9E49D291DQ51617592-3AFDF294-AD80-4F47-93AB-3226D07DAF2AQ55248632-3883988C-D08B-49DF-A0FD-8E6E21EEE1E5Q58764962-1941885A-5C57-4E93-A100-118E10E7ADA1
P2860
In vivo cleaved CDCP1 promotes early tumor dissemination via complexing with activated β1 integrin and induction of FAK/PI3K/Akt motility signaling
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
In vivo cleaved CDCP1 promotes ...... AK/PI3K/Akt motility signaling
@en
In vivo cleaved CDCP1 promotes ...... K/PI3K/Akt motility signaling.
@nl
type
label
In vivo cleaved CDCP1 promotes ...... AK/PI3K/Akt motility signaling
@en
In vivo cleaved CDCP1 promotes ...... K/PI3K/Akt motility signaling.
@nl
prefLabel
In vivo cleaved CDCP1 promotes ...... AK/PI3K/Akt motility signaling
@en
In vivo cleaved CDCP1 promotes ...... K/PI3K/Akt motility signaling.
@nl
P2093
P2860
P356
P1433
P1476
In vivo cleaved CDCP1 promotes ...... AK/PI3K/Akt motility signaling
@en
P2093
P2860
P2888
P304
P356
10.1038/ONC.2012.547
P407
P577
2012-12-03T00:00:00Z